Slaughter and May, Hong Kong, advised the placing agent, a major international investment bank, in relation to the HK$2.12 billion (US$272 million) secondary placing and sale of shares in Lijun International Pharmaceutical (Holding) Co., Ltd. (Lijun), held by Prime United Industries Limited. The placing and sale of shares represents 26.28% of the issued share capital of Lijun and was undertaken by way of an accelerated bookbuilding process to institutional investors, and a sale to the chief executive officer of Lijun and Sichuan Kelun Pharmaceutical Co., Ltd., a third party corporate investor.

Lijun is a leading pharmaceutical manufacturer in the PRC and is listed on the Main Board of The Stock Exchange of Hong Kong Limited.

CONTACTS

Corporate and Commercial: Benita Yu (partner), John Moore (partner), William Ho (associate), Norman Ho (associate)